[Clinical results with verapamil in intravenous administration in the emergency therapy of cardiac arrhythmias].
Verapamil was administered intravenously to 250 patients aged between 14 and 85, suffering from tachyarrhythmia of various type. The commonest heart conditions were hypertensive cardiopathy, acquired valvular defects, and ischaemic cardiopathy. The antiarrhythmia effectiveness of the treatment is shown by the excellent results obtained in sinus tachycardia, supraventricular paroxysmal tachycardia, high frequency atrial fibrillations and even in a patient with WPW syndrome and supraventricular paroxysmal tachycardia and in one of the 5 patients with ventricular tachycardia. Generally speaking, the treatment was continued orally in a dose of 240 mg per day, and it was possible to control the clinical situation with no side effects.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001145:Arrhythmias, Cardiac / Q000188:drug therapy* / Q000209:etiology; D001281:Atrial Fibrillation / Q000188:drug therapy; D003327:Coronary Disease / Q000150:complications; D005260:Female; D006330:Heart Defects, Congenital / Q000150:complications; D006349:Heart Valve Diseases / Q000150:complications; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D013610:Tachycardia / Q000188:drug therapy; D013614:Tachycardia, Paroxysmal / Q000188:drug therapy; D014693:Ventricular Fibrillation / Q000188:drug therapy; D014700:Verapamil / Q000008:administration & dosage / Q000627:therapeutic use*; D014927:Wolff-Parkinson-White Syndrome / Q000188:drug therapy
D014700:Verapamil
Risultati clinici con Verapamil per via endovenosa nella terapia d'urgenza delle aritmie cardiache